Connection
Mark Clements to Prostatic Neoplasms
This is a "connection" page, showing publications Mark Clements has written about Prostatic Neoplasms.
|
|
Connection Strength |
|
|
|
|
|
2.758 |
|
|
|
-
Hao S, Karlsson A, Heintz E, Elfstr?m KM, Nordstr?m T, Clements M. Cost-Effectiveness of Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study. Value Health. 2021 12; 24(12):1763-1772.
Score: 0.813
-
Hao S, ?stensson E, Eklund M, Gr?nberg H, Nordstr?m T, Heintz E, Clements M. The economic burden of prostate cancer - a Swedish prevalence-based register study. BMC Health Serv Res. 2020 May 20; 20(1):448.
Score: 0.747
-
Nordstr?m T, Annerstedt M, Glaessgen A, Carlsson S, Clements M, Abbadi A, Gr?nberg H, J?derling F, Eklund M, Discacciati A. Repeated Prostate Cancer Screening Using Prostate-Specific Antigen Testing and Magnetic Resonance Imaging: A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial. JAMA Netw Open. 2024 Feb 05; 7(2):e2354577.
Score: 0.242
-
M?ller A, Schwamborn K, Spillmann A, Hoogstraate J, Szulkin R, Akre O, Egevad L, Clements M, Aly M. Travel vaccines are strongly associated to reduced mortality in prostate cancer patients - a real effect or residual confounding? Vaccine. 2022 06 15; 40(27):3797-3801.
Score: 0.215
-
Nordstr?m T, Discacciati A, Bergman M, Clements M, Aly M, Annerstedt M, Glaessgen A, Carlsson S, J?derling F, Eklund M, Gr?nberg H. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncol. 2021 09; 22(9):1240-1249.
Score: 0.204
-
Nair-Shalliker V, Bang A, Egger S, Clements M, Gardiner RA, Kricker A, Seibel MJ, Chambers SK, Kimlin MG, Armstrong BK, Smith DP. Post-treatment levels of plasma 25- and 1,25-dihydroxy vitamin D and mortality in men with aggressive prostate cancer. Sci Rep. 2020 05 08; 10(1):7736.
Score: 0.186
-
Plym A, Clements M, Voss M, Holmberg L, Stattin P, Lambe M. Duration of sick leave after active surveillance, surgery or radiotherapy for localised prostate cancer: a nationwide cohort study. BMJ Open. 2020 03 09; 10(3):e032914.
Score: 0.184
-
Palsdottir T, Nordstr?m T, Aly M, J?derling F, Clements M, Gr?nberg H, Eklund M. A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging. Eur Urol Oncol. 2019 09; 2(5):490-496.
Score: 0.167
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|